Connect with us

Business

Novavax chief ‘not able to predict’ Australian approval date for vaccine – Sydney Morning Herald

The company behind the third major COVID vaccine that Australia has ordered has been delayed in filing for global approvals.

Published

on

Article feature image

The chief executive of coronavirus vaccine maker Novavax has admitted the company will have to delay filing for approvals of the product until July and will not put a date on when the vaccine is likely to receive the green light in Australia.
The Australian government has ordered 51 million doses of the Novavax vaccine, which had been expected to start being delivered as early as September this year.
Novavax said the trial, which enrolled 15,000 people aged 18 to 84, was expected to be used to apply…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

2 highly rated ASX 200 growth shares analysts love
ASX 200 rises, Afterpay soars, Zip jumps on Monday 2 August 2021